Compare Mesoblast Limited (MESO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Match Group Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Match Group Inc trades at $39.02 (market cap $9.10B). The key difference: Match Group Inc is far larger — about 4.2× Mesoblast Limited's market cap, and Match Group Inc pays a 2.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MTCH | |
|---|---|---|
Market Cap | $2.17B | $9.10B |
Sector | Technology | Media |
52-Week High | $20.96 | $40.29 |
52-Week Low | $12.88 | $28.90 |
Enterprise Value | $2.17B | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MTCH trades at $39.10, down 0.13% today, with a bullish technical outlook supported by moving averages and key resistance at $40. The company reported Q1 2026 revenue growth of 4% but missed EPS expectations. Strong profitability is evident with a 73.8% gross margin and 17.59% net margin. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The stock presents a moderate buy opportunity with a consensus price target of $41.63, offering ~6% upside. Risks include Tinder's user declines and high debt levels, but valuation multiples like a P/E of 14.94 suggest potential undervaluation. Investor sentiment is positive, with no analyst sell ratings, though execution on user growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
